Effectiveness of Vibrating Mesh Versus Small Volume Nebuliser in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

A Randomized Controlled Trial of Bronchodilator Delivery by Vibrating Mesh (VM) Nebuliser Versus Small Volume Nebuliser During an Acute Exacerbation of COPD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03286855
• Other study ID #: INCA NEB
• Status: Completed
• Phase: N/A
• Start date: October 18, 2017
• Est. completion date: September 30, 2018

Study information

• Verified date: July 2019
• Source: Beaumont Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

When patients get an attack of COPD, one of the main treatments is regular nebulised medications called bronchodilators. These medications act by opening up the airways allowing patients to breathe easier and to reduce shortness of breath. Newer nebulisers may increase the amount of medication that gets into the lungs compared to the standard nebuliser usually used in hospital. This study is being done to assess whether increasing the amount of medication getting into the lungs using these newer nebulisers will help patients recover from a COPD exacerbation.

Description:

COPD is a common chronic respiratory disease. It is characterised by repeated episodes of acute worsening of symptoms of cough, wheeze and breathlessness called exacerbations. Exacerbations result in patients having to present to hospital for treatment. In Ireland more than one-fifth of all inpatient hospital days for the treatment of respiratory complaints are for the treatment of COPD. The administration of bronchodilators (medication to open the airway) is a central component of the treatment of COPD exacerbation. In the hospital setting these are most commonly administered via a nebuliser. The standard of care in our institution is the Hudson micromist small volume nebuliser.

However, previous studies have shown that Vibrating mesh (VM) nebulisers result in greater deposition of medication to the lungs compared to small volume nebulisers. In addition they resulted in greater improvements in lung function and breathlessness.

This study will assess the efficacy of the Aerogen Ultra VM nebuliser in a real-world setting. The VM nebuliser is readily available for use in the clinical setting and is used to administer bronchodilator therapy, within the terms of its CE Mark. This nebuliser is already in routine use in hospitals within the Royal College of Surgeons in Ireland (RCSI) hospital group.

Patients hospitalised with an exacerbation of COPD will be recruited. There will be two study groups. Group 1 (VM Group): will receive bronchodilator (salbutamol 2.5mg/ipratropium 0.5mg) by Vibrating Mesh Nebuliser (Aerogen Ultra) with facemask and Group 2 (Standard Hospital Care): will receive bronchodilator by small volume nebuliser (Hudson Micromist) via facemask as per standard care.

Both groups will receive bronchodilator therapy four times a day which has already been prescribed by their medical team, and in accordance with recommended guidelines for treatment of COPD exacerbations. Patients will use the nebuliser for the duration of hospital stay or a maximum of 7 days. Lung function and breathlessness scores will be recorded. The aim of this study is to demonstrate that better medication delivery by VM nebulizer during an exacerbation of COPD will lead to greater bronchodilation, shorter recovery time and reduced hospital length of stay.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: September 30, 2018
• Est. primary completion date: June 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Admission with acute exacerbation of COPD within 24 hours of presentation to hospital

• Age >40

• Confirmed COPD diagnosis (FEV1/FVC <0.70 on spirometry)

• Willing to participate in the study and provide informed consent

Exclusion Criteria:

• Admission for reason other than COPD exacerbation e.g. Heart Failure

• Acute confusion as per clinical team

• Allergy or contraindication to combined bronchodilator medication

• Severe respiratory sepsis as evident by temperature >38 degrees and/or lobar pneumonia on Chest Radiograph

• Sustained tachycardia >120bpm

• Patients with very advanced COPD, admitted for palliative or long term care

• Patients re-admitted within 90 days who have already been enrolled in the study.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• COPD
• COPD Exacerbation
• Copd Exacerbation Acute
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Device:
• Vibrating Mesh Nebuliser
The Aerogen Ultra vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
• Standard Hospital Care
The "standard hospital care" refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications. This is the Hudson micromist small volume nebuliser.

Locations

Country	Name	City	State
Ireland	Beaumont Hospital	Dublin

Sponsors (2)

Lead Sponsor	Collaborator
Beaumont Hospital	Aerogen

Country where clinical trial is conducted

Ireland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Forced Vital Capacity (FVC)	Forced spirometry measured at bedside	Up to 7 days
Secondary	Change in Borg breathlessness score	Change in patient-reported breathlessness as determined by the Borg breathlessness score	Up to 7 days
Secondary	Length of Hospital Stay	Defined as time from randomisation to medical decision to discharge patient	Up to 7 days
Secondary	Change in Inspiratory Capacity (IC)	Relaxed spirometry measured at bedside	Up to 7 days
Secondary	Rate of re-exacerbation at Day 30	The number of repeat exacerbations following discharged from hospital. Exacerbation defined as an acute change in respiratory symptoms necessitating administration of antibiotics and/or steroids	Up to 30 days
Secondary	Time to re-exacerbation .	The time to first repeat exacerbation following discharge.Exacerbation defined as an acute change in respiratory symptoms necessitating administration of antibiotics and/or steroids	Up to 30 days
Secondary	Change in quality of life (QOL): to discharge and to Day 30	COPD Assessment Test Score	Up to 30 days
Secondary	Personal Satisfaction Score	End-user questionnaire	Up to 7 days
Secondary	Change in Forced Expiratory Volume in one second (FEV1)	Forced spirometry measured at bedside	Up to 7 days